{"kind":"task","effective_mode":"full","benchmark":{"kind":"benchmark","effective_mode":"full","slug":"longbench-v2","formal_name":"LongBench v2","introduction":"LongBench v2 evaluates deep understanding and reasoning over long contexts through multiple-choice questions. Its official description lists 503 questions spanning tasks such as single-document and multi-document QA and code-repository understanding.","introduction_ja":"","introduction_en":"","category":"Category not supplied","task_count":null,"acquisition_status":"Acquisition status not supplied","official_url":"https://huggingface.co/datasets/zai-org/LongBench-v2","indexing_mode":"noindex","profile":{"resources":[],"task_format":"","scoring":"","metric":"","size":"","answer_access":"","license":"","citation":"","maintainer":"","released":"","why_hard":"","related":[]}},"task_id":"e044a872-c044-52ef-b449-88c18e562310","task_key":"train--66fa6867bb02136c067c6b3b","task_revision_id":"3","upstream_id":"66fa6867bb02136c067c6b3b","short_description":"Based on the press release about Sanofi's product Dupixent, how do you know…","config":"","split":"train","body":"{\"choice_A\":\"Dupixent has been approved for marketing in more than 30 countries worldwide. For the US, the FDA's approval was primarily due to the significant data of BOREAS and NOTUS from the Phase 3 study, which demonstrated the good efficacy and safety of Dupixent.\",\"choice_B\":\"EoE is a chronic, progressive disease associated with Type 2 inflammation that severely affects children's ability to eat, and Dupixent has been approved for the treatment of this disease in more than 60 countries. Recently, the CHMP officially approved Dupixent for the treatment of patients aged 1-11, weighing more than 15kg, with inadequately controlled, intolerant, or unsuitable for conventional drug treatment\",\"choice_C\":\"Studies have shown that Dupixent can be used to treat chronic diseases such as bullous pemphigoid, chronic spontaneous urticaria, eosinophilic esophagitis, and chronic obstructive pulmonary disease (for part or all of the patients), and it has been approved for use in the United States, Europe, and other major markets of Sanofi.\",\"choice_D\":\"Dupixent is a monoclonal antibody that primarily works by inhibiting the signaling pathways of interleukin-4 (IL-4) and interleukin-13 (IL-13). The company still has several clinical studies on the treatment of Dupixent indications, including chronic pruritus of unknown origin and bullous pemphigoid.\",\"context\":\"1/6 \\n1/6 \\n \\n \\n \\n \\n \\n \\n \\nPress Release \\n \\n \\nDupixent is the first and only biologic to achieve \\nsignificant improvements in disease remission and \\nsymptoms in bullous pemphigoid positive pivotal study \\n \\n• \\nStudy met the primary and all key secondary endpoints in adults with moderate-to-\\nsevere disease; five times more patients achieved sustained disease remission with \\nDupixent than placebo \\n• \\nDupixent is the first medicine to show significant steroid-sparing effect in this \\ndebilitating and life-threatening disease  \\n• \\nIf approved, Dupixent would be the first and only targeted medicine to treat BP in the \\nU.S. and European Union \\n \\nParis and Tarrytown, NY, September 11, 2024. A Dupixent (dupilumab) pivotal study \\n(ADEPT) in bullous pemphigoid (BP) met the primary and all key secondary endpoints \\nevaluating its investigational use in adults with moderate-to-severe disease. In the study, \\nfive times more Dupixent patients achieved sustained disease remission compared to those \\non placebo. Sustained disease remission was defined as complete clinical remission with \\ncompletion of oral corticosteroids (OCS) taper by week 16 without relapse and no rescue \\ntherapy use during the 36-week treatment period. Dupixent was previously granted Orphan \\nDrug Designation by the U.S. Food and Drug Administration for BP, which applies to \\ninvestigational medicines intended for the treatment of rare diseases that affect fewer than \\n200,000 people in the U.S. This study will support regulatory submissions around the world, \\nstarting with the U.S. later this year. \\n \\nBP, a chronic and relapsing disease, is characterized by intense itch and blisters, reddening \\nof the skin, and painful chronic lesions. The blisters and rash can form over much of the \\nbody and cause the skin to bleed and crust, resulting in patients being more prone to \\ninfection and affecting their daily functioning.  \\n \\nDietmar Berger, M.D., Ph.D. \\nChief Medical Officer, Global Head of Development at Sanofi \\n“The itchy blisters caused by bullous pemphigoid can be so intense they are debilitating, especially \\nfor elderly patients. There is a significant unmet medical need for new medicines for people suffering \\nwith this hard-to-treat disease in which the standard of care is oral and topical corticosteroids and \\nimmunosuppressants – treatments that have poor clinical outcomes and safety concerns, \\nrespectively, and should be used sparingly in an elderly population. These positive pivotal results for \\nbullous pemphigoid add to an immense body of scientific evidence that underscores the important \\nrole IL4 and IL13 play in driving diseases characterized by itch. Combined with the consistent safety \\nprofile of the other dermatology indications, these results show the potential of Dupixent to \\ntransform the treatment paradigm for bullous pemphigoid.” \\n \\nIn the ADEPT study, 106 adults with moderate-to-severe BP were randomized to receive \\nDupixent 300 mg (n=53) every two weeks after an initial loading dose or placebo (n=53), \\n\\n\\n2/6 \\n2/6 \\n \\n \\n \\n \\n \\n \\n \\nalong with standard-of-care OCS. During treatment, all patients underwent a protocol-\\ndefined OCS tapering regimen if control of disease activity was maintained.  \\n \\nFor the primary endpoint, 20% of Dupixent patients experienced sustained disease \\nremission at 36 weeks compared to 4% for placebo (p=0.0114). For the components \\ncomprising the primary endpoint – with patients having to achieve all components – efficacy \\namong patients receiving Dupixent compared to placebo was as follows*: \\n \\n• \\nAbsence of disease relapse after patient completed OCS taper: 59% vs. 16% \\n(nominal p=0.0023) \\n• \\nAbsence of need for rescue therapy during treatment period: 42% vs. 12% (nominal \\np=0.0004) \\n• \\nAchievement of complete remission and off OCS by week 16: 38% vs. 27% (not \\nsignificant) \\n \\n*Components were not separately included in pre-specified statistical analyses and are \\ntherefore nominal \\n \\nFor selected secondary endpoints, results for Dupixent compared to placebo were \\nstatistically significant as follows:  \\n• \\nPatients achieving ≥90% reduction in disease severity: 41% vs. 10% (p=0.0003) \\n• \\nPatients achieving clinically meaningful itch reduction: 40% vs. 11% (p=0.0006) \\n• \\nSecondary endpoints assessing decreased OCS use, and time to use of rescue \\nmedications, also favored Dupixent and were significant (p=0.0220 and p=0.0016, \\nrespectively) \\n• \\nReduction in disease severity from baseline: 77% vs. 51% (p=0.0021) \\n• \\nReduction in itch from baseline: 52% vs. 27% (p=0.0021) \\n• \\nDays of complete remission off OCS: 40 vs. 13 (p=0.0072) \\n \\nIn this older population, overall rates of adverse events (AEs) were 96% (n=51) for \\nDupixent and 96% (n=51) for placebo. AEs more commonly observed with Dupixent \\ncompared to placebo in more than 3 patients included peripheral edema (n=8 vs. n=5), \\narthralgia (n=5 vs. n=3), back pain (n=4 vs. n=2), blurred vision (n=4 vs. n=0), \\nhypertension (n=4 vs. n=3), asthma (n=4 vs. n=1), conjunctivitis (n=4 vs. n=0), \\nconstipation (n=4 vs. n=1), upper respiratory tract infection (n=3 vs. n=1), limb injury \\n(n=3 vs. n=2), and insomnia (n=3 vs. n=2). There were no AEs leading to death in the \\nDupixent group and 2 AEs leading to death in the placebo group. \\n \\nGeorge D. Yancopoulos, M.D., Ph.D. \\nBoard co-Chair, President, and Chief Scientific Officer at Regeneron  \\n“Bullous pemphigoid is a debilitating skin disease with a high mortality rate due to infection. \\nDupixent is the first medication to show significant and robust impacts in this patient population. \\nThese latest pivotal results reaffirm the underlying role type-2 inflammation plays in driving \\nmultiple skin diseases. We look forward to further advancing this research and sharing the positive \\nresults from the bullous pemphigoid pivotal trial with regulatory authorities.”  \\n \\nAdditionally, a small separate phase 3 study (Study A) evaluating the investigational use of \\nDupixent in adults with uncontrolled and severe chronic pruritus of unknown origin (CPUO) \\ndid not achieve statistical significance in its primary itch responder endpoint (despite \\nfavorable numerical improvements), but showed nominally significant improvements in all \\n\\n\\n3/6 \\n3/6 \\n \\n \\n \\n \\n \\n \\n \\nother itch endpoints including: change from baseline; percent of patients achieving no/mild \\nitch; and change in itch-related quality of life from baseline. Safety results were generally \\nconsistent with the known safety profile of Dupixent in its approved dermatological \\nindications. The Dupixent phase 3 study program in CPUO consists of Study A and Study B. \\nStudy B is planned to initiate as a subsequent pivotal study. \\nDetailed efficacy and safety results for both BP and CPUO studies are planned for \\npresentation at a forthcoming medical meeting. \\n \\nThe safety and efficacy of Dupixent in BP and CPUO are currently under clinical investigation \\nand have not been evaluated by any regulatory authority. \\n \\nAbout the Dupixent BP pivotal study  \\nADEPT is a randomized, phase 2/3, double-blind, placebo-controlled study evaluating the \\nefficacy and safety of Dupixent in 106 adults with moderate-to-severe BP for a 52-week \\ntreatment period. After randomization, patients received Dupixent or placebo every two \\nweeks, with OCS treatment. During treatment, OCS taper was initiated after patients \\nexperienced two weeks of sustained control of disease activity. OCS tapering could start \\nbetween four to six weeks after randomization and was continued as long as disease control \\nwas maintained, with the intent of completion by 16 weeks. After OCS tapering, patients \\nwere only treated with Dupixent or placebo for at least 20 weeks, unless rescue treatment \\nwas required. \\n \\nThe primary endpoint evaluated the proportion of patients achieving sustained disease \\nremission at 36 weeks. Sustained disease remission was defined as complete clinical \\nremission with completion of OCS taper by 16 weeks without relapse and no rescue therapy \\nuse during the 36-week treatment period. Relapse was defined as appearance of ≥3 new \\nlesions a month or ≥1 large lesion (>10cm in diameter) that did not heal within a week. \\nRescue therapy could include treatment with high-potency topical corticosteroids, OCS \\n(including increase of OCS dose during the taper or re-initiation of OCS after completion of \\nthe OCS taper), systemic non-steroidal immunosuppressive medications, or \\nimmunomodulating biologics. \\n \\nSelect secondary endpoints evaluated at 36 weeks included: \\n• \\nProportion of patients achieving ≥90% reduction in Bullous Pemphigoid Disease Area \\nIndex (BPDAI; scale:0-360) \\n• \\nProportion of patients with ≥4-point reduction in Peak Pruritus Numerical Rating \\nScale (PP-NRS; scale 0-10) \\n• \\nTotal cumulative OCS dose \\n• \\nTime to first use of rescue medication \\n• \\nPercent change from baseline in BPDAI \\n• \\nPercent change in weekly average of daily PP-NRS \\n• \\nDuration of complete remission while not requiring OCS \\n \\nAbout the Dupixent CPUO phase 3 program \\nThe Dupixent phase 3 program in CPUO consists of Study A and Study B. Study A was a \\nrandomized, phase 3, double-blind, placebo-controlled study evaluating the efficacy and \\nsafety of Dupixent in adults with uncontrolled, severe CPUO. During the 4-week run-in \\nperiod, patients received a standard-of-care regimen comprised of a non-sedative \\nantihistamine and moisturizer to confirm they were refractory to available options. During \\n\\n\\n4/6 \\n4/6 \\n \\n \\n \\n \\n \\n \\n \\nthe following 24-week treatment period, patients received Dupixent or placebo every two \\nweeks added to the standard-of-care regimen. \\n \\nThe primary endpoint evaluated the proportion of patients with a clinically meaningful \\nimprovement in itch from baseline at 24 weeks, measured by a ≥4-point reduction in the \\nworst-itch numerical rating scale (WI-NRS; scale: 0-10). The key secondary endpoint \\nevaluated the proportion of patients with a ≥4-point reduction in WI-NRS at 12 weeks. \\nAdditional secondary endpoints included: \\n• \\nProportion of patients achieving no/mild pruritus on Patient Global Impression of \\nSeverity (PGIS) of pruritus \\n• \\nAbsolute change and percent change from baseline in the weekly average of daily \\nitch-related sleep disturbances at 24 weeks measured by the sleep disturbance NRS \\n(scale: 0-10) \\n• \\nAbsolute change from baseline in itch-related quality of life measured by the \\nItchyQoL (scale: 22-110)  \\n• \\nAbsolute change from baseline in health-related quality of life at 24 weeks measured \\nby the Dermatology Life Quality Index (scale: 0-30) \\n \\nStudy B is planned to initiate as a subsequent pivotal study. \\n \\nAbout Dupixent \\nDupixent (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the \\ninterleukin-4 (IL4) and interleukin-13 (IL13) pathways and is not an immunosuppressant. \\nThe Dupixent development program has shown significant clinical benefit and a decrease in \\ntype-2 inflammation in phase 3 studies, establishing that IL4 and IL13 are key and central \\ndrivers of the type-2 inflammation that plays a major role in multiple related and often co-\\nmorbid diseases. \\n \\nDupixent has received regulatory approvals in more than 60 countries in one or more \\nindications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis \\nwith nasal polyposis, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous \\nurticaria, and chronic obstructive pulmonary disease in different age populations. More than \\n1,000,000 patients are being treated with Dupixent globally. \\n \\nDupilumab development program \\nDupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration \\nagreement. To date, dupilumab has been studied across more than 60 clinical studies \\ninvolving more than 10,000 patients with various chronic diseases driven in part by type-2 \\ninflammation. \\n \\nIn addition to the currently approved indications, Sanofi and Regeneron are studying \\ndupilumab in a broad range of diseases driven by type-2 inflammation or other allergic \\nprocesses in phase 3 studies, including chronic pruritus of unknown origin and bullous \\npemphigoid. These potential uses of dupilumab are currently under clinical investigation, \\nand the safety and efficacy in these conditions have not been fully evaluated by any \\nregulatory authority. \\n \\nAbout Regeneron \\nRegeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and \\ncommercializes life-transforming medicines for people with serious diseases. Founded and \\n\\n\\n5/6 \\n5/6 \\n \\n \\n \\n \\n \\n \\n \\nled by physician-scientists, our unique ability to repeatedly and consistently translate \\nscience into medicine has led to numerous approved treatments and product candidates in \\ndevelopment, most of which were homegrown in our laboratories. Our medicines and \\npipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, \\ncancer, cardiovascular and metabolic diseases, neurological diseases, hematologic \\nconditions, infectious diseases, and rare diseases. \\n \\nRegeneron pushes the boundaries of scientific discovery and accelerates drug \\ndevelopment using our proprietary technologies, such as VelociSuite®, which produces \\noptimized fully human antibodies and new classes of bispecific antibodies. We are shaping \\nthe next frontier of medicine with data-powered insights from the Regeneron Genetics \\nCenter® and pioneering genetic medicine platforms, enabling us to identify innovative \\ntargets and complementary approaches to potentially treat or cure diseases. \\n \\nFor more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, \\nInstagram, Facebook or X. \\n \\nAbout Sanofi  \\nWe are an innovative global healthcare company, driven by one purpose: we chase the \\nmiracles of science to improve people’s lives. Our team, across the world, is dedicated to \\ntransforming the practice of medicine by working to turn the impossible into the possible. \\nWe provide potentially life-changing treatment options and life-saving vaccine protection to \\nmillions of people globally, while putting sustainability and social responsibility at the center \\nof our ambitions. \\nSanofi is listed on EURONEXT: SAN and NASDAQ: SNY \\n \\nSanofi Media Relations \\nSandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.com \\nEvan Berland | + 1 215 432 0234 | evan.berland@sanofi.com \\nVictor Rouault | + 33 6 70 93 71 40 | victor.rouault@sanofi.com \\nTimothy Gilbert | + 1 516 521 2929 | timothy.gilbert@sanofi.com \\n \\nSanofi Investor Relations \\nThomas Kudsk Larsen |+ 44 7545 513 693 | thomas.larsen@sanofi.com \\nAlizé Kaisserian | + 33 6 47 04 12 11 | alize.kaisserian@sanofi.com \\nArnaud Delépine | + 33 6 73 69 36 93 |arnaud.delepine@sanofi.com \\nFelix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.com \\nKeita Browne | + 1 781 249 1766 | keita.browne@sanofi.com \\nNathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.com \\nTarik Elgoutni | + 1 617 710 3587 | tarik.elgoutni@sanofi.com \\nThibaud Châtelet | + 33 6 80 80 89 90 | thibaud.chatelet@sanofi.com \\n \\nRegeneron Media Relations \\nIlana Yellen | +1 914-330-9618| ilana.yellen@regeneron.com  \\n  \\nRegeneron Investor Relations \\nVesna Tosic | + 914-847-5443 | vesna.tosic@regeneron.com \\n \\nSanofi Forward-Looking Statements \\nThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as \\namended. Forward-looking statements are statements that are not historical facts. These statements include projections and \\nestimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to \\nfuture financial results, events, operations, services, product development and potential, and statements regarding future \\nperformance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, \\n“estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such \\nforward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to \\nvarious risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause \\n\\n\\n6/6 \\n6/6 \\n \\n \\n \\n \\n \\n \\n \\nactual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking \\ninformation and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and \\ndevelopment, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the \\nEMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product \\ncandidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential \\nof such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval \\nand commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete \\nrelated transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or \\nfuture litigation and the ultimate outcome of such litigation,  trends in exchange rates and prevailing interest rates, volatile \\neconomic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that pandemics or \\nother global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of \\nany one of them, as well as on our employees and on the global economy as a whole.  The risks and uncertainties also include the \\nuncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under \\n“Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the \\nyear ended December 31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation to update or \\nrevise any forward-looking information or statements. \\n \\nAll trademarks mentioned in this press release are the property of the Sanofi group apart from VelociSuite and Regeneron Genetics \\nCenter. \\n \\nRegeneron Forward-Looking Statements and Use of Digital Media  \\nThis press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future \\nperformance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ \\nmaterially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” \\n“estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not \\nall forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties \\ninclude, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise \\ncommercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates \\nbeing developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research \\nand clinical programs now underway or planned, including without limitation Dupixent® (dupilumab); the likelihood, timing, and \\nscope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for \\nRegeneron’s Products, such as Dupixent for the treatment of bullous pemphigoid and/or chronic pruritus of unknown origin as \\ndiscussed in this press release as well as other potential indications; uncertainty of the utilization, market acceptance, and \\ncommercial success of Regeneron’s Products and Regeneron’s Product Candidates and the impact of studies (whether conducted by \\nRegeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on \\nany of the foregoing or any potential regulatory approval of Regeneron’s Products (such as Dupixent) and Regeneron’s Product \\nCandidates; the extent to which the results from the research and development programs conducted by Regeneron and/or its \\ncollaborators or licensees (including the studies discussed or referenced in this press release) may be replicated in other studies \\nand/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; the ability of \\nRegeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, \\npackaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability \\nof Regeneron to manage supply chains for multiple products and product candidates; safety issues resulting from the administration \\nof Regeneron’s Products (such as Dupixent) and Regeneron’s Product Candidates in patients, including serious complications or side \\neffects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; determinations by \\nregulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or \\ncommercialize Regeneron’s Products and Regeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting \\nRegeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and \\nextent of reimbursement of Regeneron’s Products from third-party payers, including private payer healthcare and insurance \\nprograms, health maintenance organizations, pharmacy benefit management companies, and government programs such as \\nMedicare and Medicaid; coverage and reimbursement determinations by such payers and new policies and procedures adopted by \\nsuch payers; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron’s Products \\nand Regeneron’s Product Candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability \\nof Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or \\nguidance; the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and \\nBayer (or their respective affiliated companies, as applicable) to be cancelled or terminated; the impact of public health outbreaks, \\nepidemics, or pandemics (such as the COVID-19 pandemic) on Regeneron's business; and risks associated with intellectual property \\nof other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related \\nproceedings relating to EYLEA® (aflibercept) Injection), other litigation and other proceedings and government investigations \\nrelating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of \\nJustice and the U.S. Attorney's Office for the District of Massachusetts), the ultimate outcome of any such proceedings and \\ninvestigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial \\ncondition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities \\nand Exchange Commission, including its Form 10-K for the year ended December 31, 2023 and its Form 10-Q for the quarterly \\nperiod ended June 30, 2024. Any forward-looking statements are made based on management’s current beliefs and judgment, and \\nthe reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any \\nobligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or \\nguidance, whether as a result of new information, future events, or otherwise.  \\nRegeneron uses its media and investor relations website and social media outlets to publish important information about the \\nCompany, including information that may be deemed material to investors. Financial and other information about Regeneron is \\nroutinely posted and is accessible on Regeneron's media and investor relations website (https://investor.regeneron.com) and its \\nLinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals). \\n \\n\\n\\n1/5 \\n1/5 \\n \\n \\n \\n \\n \\n \\n \\nPress Release \\n \\n \\nDupixent phase 3 study confirms significant \\nimprovements in itch and hives for patients with CSU  \\n \\n• \\nConfirming the results of CUPID-A, this second pivotal study in biologic-naïve \\npatients met primary and key secondary endpoints, showing treatment with \\nDupixent resulted in a nearly 50% reduction in itch and urticaria activity scores  \\n• \\nMore than 300,000 people in the US suffer from chronic spontaneous urticaria \\n(CSU) that is inadequately controlled by antihistamines \\n• \\nData will support regulatory resubmission in the US by year-end; if approved, \\nDupixent would be the first targeted therapy for CSU in a decade \\nParis and Tarrytown, NY, September 11, 2024. A Dupixent (dupilumab) confirmatory \\nphase 3 study (LIBERTY-CUPID Study C) met the primary and key secondary endpoints for \\nthe investigational treatment of patients with uncontrolled, biologic-naïve CSU receiving \\nbackground therapy with antihistamines. CSU is a chronic skin condition that causes sudden \\nand debilitating hives and persistent itch, which can impact quality of life. This positive \\nstudy confirms results from Study A, the first phase 3 study of Dupixent in this setting. \\nEarlier this year, Japan was the first country in the world to approve and launch Dupixent \\nfor adult and adolescent CSU patients based on the results from Study A. \\nDietmar Berger, M.D., Ph.D. \\nChief Medical Officer, Global Head of Development at Sanofi \\n“The positive pivotal data from this study reinforce the potential of Dupixent to offer a new treatment \\noption for the many people suffering from chronic spontaneous urticaria who do not respond to \\nstandard-of-care antihistamines. With clinically meaningful reductions in itch and hives for patients \\nreceiving Dupixent, we look forward to sharing these data with the FDA to bring Dupixent to patients \\nwith CSU in the US as soon as possible. With Dupixent now treating 1 million patients across seven \\napproved indications, these new results underscore there are still many more patients that Dupixent \\ncan potentially benefit.” \\n \\nStudy C enrolled 151 children and adults randomized to receive Dupixent (n=74) or placebo \\n(n=77) added to standard-of-care histamine-1 (H1) antihistamines. At 24 weeks, efficacy \\namong patients receiving Dupixent compared to placebo was as follows:  \\n \\n• \\n8.64-point reduction in itch severity from baseline with Dupixent versus a 6.10-point \\nreduction with placebo (p=0.02) \\n• \\n15.86-point reduction in urticaria activity (itch and hive) severity from baseline with \\nDupixent versus an 11.21-point reduction with placebo (p=0.02) \\n \\nNotably, 30% of Dupixent-treated patients reported no urticaria (complete response), \\ncompared to 18% of those on placebo (p=0.02). \\n \\nThe safety results were generally consistent with the known safety profile of Dupixent in its \\napproved dermatological indications. Overall rates of treatment emergent adverse events \\n\\n\\n2/5 \\n2/5 \\n \\n \\n \\n \\n \\n \\n \\n(AE) were 53% for Dupixent and 53% for placebo. AEs more commonly observed with \\nDupixent (≥5%) compared to placebo included injection site reactions (12% vs. 4%), \\naccidental overdose (7% vs. 3%), and COVID-19 infection (8% vs. 5%). \\n \\nDetailed results from this study will be provided to the US Food and Drug Administration in \\nresponse to the additional data requested for inclusion in the supplemental biologics \\napplication for Dupixent in CSU. These data are also planned for presentation at a \\nforthcoming medical meeting. \\n \\nGeorge D. Yancopoulos, M.D., Ph.D. \\nBoard Co-Chair, President, and Chief Scientific Officer at Regeneron  \\n“Patients with uncontrolled chronic spontaneous urticaria experience debilitating itch and hives that \\nappear without warning and disrupt their lives. With a nearly 50% reduction in itch and urticaria \\nactivity scores compared to placebo, these positive phase 3 results reaffirm the potential of Dupixent \\nto bring relief and its well-established safety profile to those living with this chronic inflammatory \\nskin disease.”  \\n \\nOutside of Japan, the safety and efficacy of Dupixent for CSU has not been fully evaluated \\nby any regulatory authority. \\n \\nAbout CSU \\nCSU is a chronic inflammatory skin disease driven in part by type-2 inflammation, which \\ncauses sudden and debilitating hives and persistent itch. CSU is typically treated with H1 \\nantihistamines, medicines that target H1 receptors on cells to control symptoms of urticaria. \\nHowever, the disease remains uncontrolled despite antihistamine treatment in many \\npatients, some of whom are left with limited alternative treatment options. These individuals \\ncontinue to experience symptoms that can be debilitating and significantly impact their \\nquality of life. \\n \\nAbout the Dupixent phase 3 CSU program (LIBERTY-CUPID) \\nThe LIBERTY-CUPID Phase 3 study program evaluating Dupixent in CSU consists of Study A, \\nStudy B, and Study C.  \\n \\nStudy C was a randomized, double-blind, placebo-controlled clinical study that evaluated \\nthe efficacy and safety of Dupixent as an add-on to standard-of-care antihistamines \\ncompared to antihistamines alone in 151 patients aged six years and older with CSU who \\nremained symptomatic despite antihistamine use and were not previously treated with \\nomalizumab (i.e., biologic-naïve). The primary endpoint assessed the change from baseline \\nin itch at 24 weeks (measured by the weekly itch severity score [ISS7], 0-21 scale). A key \\nsecondary endpoint was the change from baseline in itch and hives at 24 weeks (measured \\nby the weekly urticaria activity score [UAS7], 0-42 scale). \\n \\nStudy A supported the approval of Dupixent in Japan for the treatment of CSU in people \\naged 12 years and older whose disease is not adequately controlled with existing therapy. \\n \\nResults from Study A and Study B, which assessed Dupixent in patients aged 12 years and \\nolder who were uncontrolled on standard-of-care H1 antihistamines and refractory to \\nomalizumab, were published in The Journal of Allergy and Clinical Immunology. \\n \\nAbout Dupixent \\n\\n\\n3/5 \\n3/5 \\n \\n \\n \\n \\n \\n \\n \\nDupixent (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the \\ninterleukin-4 (IL4) and interleukin-13 (IL13) pathways and is not an immunosuppressant. \\nThe Dupixent development program has shown significant clinical benefit and a decrease in \\ntype-2 inflammation in phase 3 studies, establishing that IL4 and IL13 are key and central \\ndrivers of the type-2 inflammation that plays a major role in multiple related and often co-\\nmorbid diseases. \\n \\nDupixent has received regulatory approvals in more than 60 countries in one or more \\nindications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis \\nwith nasal polyposis, eosinophilic esophagitis, prurigo nodularis, CSU, and chronic \\nobstructive pulmonary disease in different age populations. More than 1,000,000 patients \\nare being treated with Dupixent globally. \\n \\nDupilumab development program \\nDupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration \\nagreement. To date, dupilumab has been studied across more than 60 clinical studies \\ninvolving more than 10,000 patients with various chronic diseases driven in part by type-2 \\ninflammation. \\n \\nIn addition to the currently approved indications, Sanofi and Regeneron are studying \\ndupilumab in a broad range of diseases driven by type-2 inflammation or other allergic \\nprocesses in phase 3 studies, including chronic pruritus of unknown origin and bullous \\npemphigoid. These potential uses of dupilumab are currently under clinical investigation, \\nand the safety and efficacy in these conditions have not been fully evaluated by any \\nregulatory authority. \\n \\nAbout Regeneron \\nRegeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and \\ncommercializes life-transforming medicines for people with serious diseases. Founded and \\nled by physician-scientists, our unique ability to repeatedly and consistently translate \\nscience into medicine has led to numerous approved treatments and product candidates in \\ndevelopment, most of which were homegrown in our laboratories. Our medicines and \\npipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, \\ncancer, cardiovascular and metabolic diseases, neurological diseases, hematologic \\nconditions, infectious diseases, and rare diseases. \\n \\nRegeneron pushes the boundaries of scientific discovery and accelerates drug \\ndevelopment using our proprietary technologies, such as VelociSuite®, which produces \\noptimized fully human antibodies and new classes of bispecific antibodies. We are shaping \\nthe next frontier of medicine with data-powered insights from the Regeneron Genetics \\nCenter® and pioneering genetic medicine platforms, enabling us to identify innovative \\ntargets and complementary approaches to potentially treat or cure diseases. \\n \\nFor more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, \\nInstagram, Facebook or X. \\n \\nAbout Sanofi  \\nWe are an innovative global healthcare company, driven by one purpose: we chase the \\nmiracles of science to improve people’s lives. Our team, across the world, is dedicated to \\ntransforming the practice of medicine by working to turn the impossible into the possible. \\n\\n\\n4/5 \\n4/5 \\n \\n \\n \\n \\n \\n \\n \\nWe provide potentially life-changing treatment options and life-saving vaccine protection to \\nmillions of people globally, while putting sustainability and social responsibility at the center \\nof our ambitions. \\n \\nSanofi is listed on EURONEXT: SAN and NASDAQ: SNY \\n \\nSanofi Media Relations \\nSandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.com \\nEvan Berland | + 1 215 432 0234 | evan.berland@sanofi.com \\nVictor Rouault | + 33 6 70 93 71 40 | victor.rouault@sanofi.com \\nTimothy Gilbert | + 1 516 521 2929 | timothy.gilbert@sanofi.com \\n \\nSanofi Investor Relations \\nThomas Kudsk Larsen |+ 44 7545 513 693 | thomas.larsen@sanofi.com \\nAlizé Kaisserian | + 33 6 47 04 12 11 | alize.kaisserian@sanofi.com \\nArnaud Delépine | + 33 6 73 69 36 93 |arnaud.delepine@sanofi.com \\nFelix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.com \\nKeita Browne | + 1 781 249 1766 | keita.browne@sanofi.com \\nNathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.com \\nTarik Elgoutni | + 1 617 710 3587 | tarik.elgoutni@sanofi.com \\nThibaud Châtelet | + 33 6 80 80 89 90 | thibaud.chatelet@sanofi.com \\n \\nRegeneron Media Relations \\nIlana Yellen | +1 914-330-9618| ilana.yellen@regeneron.com  \\n  \\nRegeneron Investor Relations \\nVesna Tosic | + 914-847-5443 | vesna.tosic@regeneron.com \\n \\nSanofi forward-looking statements \\nThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. \\nForward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding \\nthe marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements \\nare generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. \\nAlthough Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors \\nare cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are \\ndifficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially \\nfrom those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties \\ninclude among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the \\navailability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent \\nin research and development, including future clinical data and analysis of existing clinical data relating to the product, including post \\nmarketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and \\nany related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact \\nthat pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the \\nfinancial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties \\nalso include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those \\nlisted under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-\\nF for the year ended December 31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation to \\nupdate or revise any forward-looking information or statements. \\n \\nAll trademarks mentioned in this press release are the property of the Sanofi group apart from VelociSuite and Regeneron Genetics \\nCenter. \\n \\nRegeneron Forward-Looking Statements and Use of Digital Media  \\nThis press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future \\nperformance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ \\nmaterially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” \\n“estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although \\nnot all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties \\ninclude, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise \\ncommercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates \\nbeing developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research \\nand clinical programs now underway or planned, including without limitation Dupixent® (dupilumab); the likelihood, timing, and \\nscope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for \\nRegeneron’s Products, such as Dupixent for the treatment of chronic spontaneous urticaria (“CSU”) as discussed in this press \\nrelease as well as other potential indications; uncertainty of the utilization, market acceptance, and commercial success of \\n\\n\\n5/5 \\n5/5 \\n \\n \\n \\n \\n \\n \\n \\nRegeneron’s Products and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others \\nand whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing or \\nany potential regulatory approval of Regeneron’s Products (such as Dupixent for the treatment of CSU) and Regeneron’s Product \\nCandidates; whether the results from the confirmatory Phase 3 trial discussed in this press release will be sufficient for purposes of \\nthe request from the U.S. Food and Drug Administration for additional data to include in the supplemental biologics application for \\nDupixent in CSU; the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform \\nmanufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s \\nProduct Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates; safety issues \\nresulting from the administration of Regeneron’s Products (such as Dupixent) and Regeneron’s Product Candidates in patients, \\nincluding serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product \\nCandidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict \\nRegeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; ongoing \\nregulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those \\nrelating to patient privacy; the availability and extent of reimbursement of Regeneron’s Products from third-party payers, including \\nprivate payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, \\nand government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payers and new \\npolicies and procedures adopted by such payers; competing drugs and product candidates that may be superior to, or more cost \\neffective than, Regeneron’s Products and Regeneron’s Product Candidates; the extent to which the results from the research and \\ndevelopment programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead \\nto advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; \\nthe costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or \\nguidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or \\nsupply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable) \\nto be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on \\nRegeneron's business; and risks associated with intellectual property of other parties and pending or future litigation relating \\nthereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection), \\nother litigation and other proceedings and government investigations relating to the Company and/or its operations (including the \\npending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of \\nMassachusetts), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have \\non Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other \\nmaterial risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for \\nthe year ended December 31, 2023 and its Form 10-Q for the quarterly period ended June 30, 2024. Any forward-looking \\nstatements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any \\nforward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) \\nany forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new \\ninformation, future events, or otherwise. Regeneron uses its media and investor relations website and social media outlets to \\npublish important information about the Company, including information that may be deemed material to investors. Financial and \\nother information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website \\n(https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals). \\n \\n\\n\\n1/4 \\n1/4 \\n \\n \\n \\n \\n \\nPress Release \\n \\n \\n \\nDupixent recommended for EU approval by the CHMP to \\ntreat eosinophilic esophagitis in children as young as 1 \\nyear old  \\n \\n* \\nRecommendation based on a phase 3 study showing a significantly greater proportion \\nof children on Dupixent achieved histological remission, compared to placebo, \\nconsistent with improvements seen in adults and adolescents \\n* \\nIf approved, Dupixent would be the first and only medicine in the EU indicated for EoE \\nin this age group \\n \\nParis and Tarrytown, NY, September 20, 2024. The European Medicines Agency’s \\nCommittee for Medicinal Products for Human Use (CHMP) adopted a positive opinion \\nrecommending the expanded approval of Dupixent (dupilumab) in the European Union (EU) \\nfor eosinophilic esophagitis (EoE) in children down to 1 year of age. The recommendation is \\nfor children aged 1 to 11 years who weigh at least 15 kg and who are inadequately controlled \\nby, intolerant to, or who are not candidates for conventional medicinal therapy. The European \\nCommission is expected to announce a final decision in the coming months. Dupixent is \\nalready approved in the EU for certain adults and adolescents aged 12 years and older with \\nEoE. \\n \\nThe positive CHMP opinion is supported by a two-part (Part A and B) EoE KIDS phase 3 study \\nin children aged one to 11 years. In Part A, a significantly greater proportion of children \\nreceiving weight-based doses of Dupixent achieved histological disease remission at week 16, \\ncompared to placebo, with results sustained for up to one year in Part B. At week 16, \\ncaregivers of children treated with Dupixent also observed improvements in the frequency \\nand severity of EoE signs, and fewer days with at least one sign of EoE, compared to placebo. \\nThese data established a bridge showing the response to Dupixent in children with EoE is \\nsimilar to that of the approved adult and adolescent EoE populations.  \\n \\nThe safety results in the EoE KIDS study were generally consistent with the known safety \\nprofile of Dupixent in adolescents and adults with EoE. AEs more commonly observed with \\nDupixent (≥10%) in either weight-based dosing regimen compared to placebo during Part A \\nwere COVID-19, nausea, injection site pain and headache. The long-term safety profile of \\nDupixent evaluated in Part B was similar to that observed during Part A.  \\n \\nResults from the study were recently published in The New England Journal of Medicine. \\n \\nThe use of Dupixent in children aged one to 11 years with EoE is investigational in the EU and \\nis not yet approved.  \\n \\n \\nAbout EoE \\n\\n\\n2/4 \\n2/4 \\n \\n \\n \\n \\n \\nEoE is a chronic, progressive disease associated with type-2 inflammation that is thought to \\nbe responsible for damaging the esophagus and impairing its function. Diagnosis is difficult, \\nas symptoms can be mistaken for other conditions and there are delays in diagnosis. EoE can \\nseverely impact a child’s ability to eat and may also cause vomiting, abdominal pain, difficulty \\nswallowing, decreased appetite and challenges thriving. Continuous management of EoE may \\nbe needed to reduce the risk of complications and disease progression. \\n \\nAbout Dupixent \\nDupixent (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the \\ninterleukin-4 (IL4) and interleukin-13 (IL13) pathways and is not an immunosuppressant. The \\nDupixent development program has shown significant clinical benefit and a decrease in type-\\n2 inflammation in phase 3 studies, establishing that IL4 and IL13 are key and central drivers \\nof the type-2 inflammation that plays a major role in multiple related and often co-morbid \\ndiseases. \\n \\nDupixent has received regulatory approvals in more than 60 countries in one or more \\nindications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis \\nwith nasal polyps, EoE, prurigo nodularis, chronic spontaneous urticaria, and chronic \\nobstructive pulmonary disease in different age populations. More than 1,000,000 patients are \\nbeing treated with Dupixent globally. \\n \\nDupilumab development program \\nDupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration \\nagreement. To date, dupilumab has been studied across more than 60 clinical studies \\ninvolving more than 10,000 patients with various chronic diseases driven in part by type-2 \\ninflammation. \\n \\nIn addition to the currently approved indications, Sanofi and Regeneron are studying \\ndupilumab in a broad range of diseases driven by type-2 inflammation or other allergic \\nprocesses in phase 3 studies, including chronic pruritus of unknown origin and bullous \\npemphigoid. These potential uses of dupilumab are currently under clinical investigation, and \\nthe safety and efficacy in these conditions have not been fully evaluated by any regulatory \\nauthority. \\n \\nAbout Regeneron  \\nRegeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and \\ncommercializes life-transforming medicines for people with serious diseases. Founded and led \\nby physician-scientists, our unique ability to repeatedly and consistently translate science into \\nmedicine has led to numerous approved treatments and product candidates in development, \\nmost of which were homegrown in our laboratories. Our medicines and pipeline are designed \\nto help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular \\nand metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, \\nand rare diseases.  \\n \\nRegeneron pushes \\nthe \\nboundaries \\nof \\nscientific \\ndiscovery \\nand accelerates \\ndrug \\ndevelopment using our proprietary technologies, such as VelociSuite®, which produces \\noptimized fully human antibodies and new classes of bispecific antibodies. We are shaping the \\nnext frontier of medicine with data-powered insights from the Regeneron Genetics \\nCenter® and pioneering genetic medicine platforms, enabling us to identify innovative targets \\nand complementary approaches to potentially treat or cure diseases. \\n\\n\\n3/4 \\n3/4 \\n \\n \\n \\n \\n \\n \\nFor more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, \\nInstagram, Facebook or X. \\n \\n \\nAbout Sanofi  \\nWe are an innovative global healthcare company, driven by one purpose: we chase the \\nmiracles of science to improve people’s lives. Our team, across the world, is dedicated to \\ntransforming the practice of medicine by working to turn the impossible into the possible. We \\nprovide potentially life-changing treatment options and life-saving vaccine protection to \\nmillions of people globally, while putting sustainability and social responsibility at the center \\nof our ambitions.  \\n \\nSanofi is listed on EURONEXT: SAN and NASDAQ: SNY \\n \\nSanofi Media Relations \\nSandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.com \\nEvan Berland | + 1 215 432 0234 | evan.berland@sanofi.com \\nVictor Rouault | + 33 6 70 93 71 40 | victor.rouault@sanofi.com \\nTimothy Gilbert | + 1 516 521 2929 | timothy.gilbert@sanofi.com \\n \\nSanofi Investor Relations \\nThomas Kudsk Larsen |+ 44 7545 513 693 | thomas.larsen@sanofi.com \\nAlizé Kaisserian | + 33 6 47 04 12 11 | alize.kaisserian@sanofi.com \\nArnaud Delépine | + 33 6 73 69 36 93 |arnaud.delepine@sanofi.com \\nFelix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.com \\nKeita Browne | + 1 781 249 1766 | keita.browne@sanofi.com \\nNathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.com \\nTarik Elgoutni | + 1 617 710 3587 | tarik.elgoutni@sanofi.com  \\nThibaud Châtelet | + 33 6 80 80 89 90 | thibaud.chatelet@sanofi.com \\n \\n \\nRegeneron Media Relations \\nHannah Kwagh | +1 914-847-6314| hannah.kwagh@regeneron.com \\n \\nRegeneron Investor Relations \\nVesna Tosic | + 914-847-5443 | vesna.tosic@regeneron.com \\n \\n \\n \\n \\nSanofi forward-looking statements \\nThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. \\nForward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding \\nthe marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements \\nare generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. \\nAlthough Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors \\nare cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are \\ndifficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially \\nfrom those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties \\ninclude among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the \\navailability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent \\nin research and development, including future clinical data and analysis of existing clinical data relating to the product, including post \\nmarketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and \\nany related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact \\nthat pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the \\nfinancial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties \\nalso include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those \\nlisted under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-\\nF for the year ended December 31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation to \\nupdate or revise any forward-looking information or statements. \\n\\n\\n4/4 \\n4/4 \\n \\n \\n \\n \\n \\n \\nAll trademarks mentioned in this press release are the property of the Sanofi group with the exception of VelociSuite and Regeneron \\nGenetics Center. \\n \\nRegeneron Forward-Looking Statements \\nThis press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future \\nperformance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially \\nfrom these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” \\nvariations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-\\nlooking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among \\nothers, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by \\nRegeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by \\nRegeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research and clinical programs \\nnow underway or planned, including without limitation Dupixent® (dupilumab); the impact of the opinion adopted by the European \\nMedicines Agency's Committee for Medicinal Products for Human Use discussed in this press release on the potential approval by the \\nEuropean Commission of Dupixent to treat eosinophilic esophagitis (“EoE”) in children aged 1 to 11 years; the likelihood, timing, and \\nscope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s \\nProducts, such as Dupixent for the treatment of pediatric EoE in the European Union as discussed in this press release as well as for \\nthe treatment of chronic pruritus of unknown origin, bullous pemphigoid, and other potential indications; uncertainty of the utilization, \\nmarket acceptance, and commercial success of Regeneron’s Products and Regeneron’s Product Candidates and the impact of studies \\n(whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in \\nthis press release, on any of the foregoing; the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as \\napplicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s \\nProducts and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product \\ncandidates; safety issues resulting from the administration of Regeneron’s Products (such as Dupixent) and Regeneron’s Product \\nCandidates in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and \\nRegeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which \\nmay delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product \\nCandidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and \\nbusiness, including those relating to patient privacy; the availability and extent of reimbursement of Regeneron’s Products from third-\\nparty payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit \\nmanagement companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by \\nsuch payers and new policies and procedures adopted by such payers; competing drugs and product candidates that may be superior \\nto, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates; the extent to which the results from the \\nresearch and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies \\nand/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated \\nexpenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections \\nor guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or \\nsupply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable) \\nto be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on \\nRegeneron's business; and risks associated with intellectual property of other parties and pending or future litigation relating thereto \\n(including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection), other \\nlitigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending \\ncivil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), \\nthe ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s \\nbusiness, prospects, operating results, and financial condition. A more complete description of these and other material risks can be \\nfound in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December \\n31, 2023 and its Form 10-Q for the quarterly period ended June 30, 2024. Any forward-looking statements are made based on \\nmanagement’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by \\nRegeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including \\nwithout limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.  \\nRegeneron uses its media and investor relations website and social media outlets to publish important information about the Company, \\nincluding information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted \\nand is accessible on Regeneron's media and investor relations website (https://investor.regeneron.com) and its LinkedIn page \\n(https://www.linkedin.com/company/regeneron-pharmaceuticals). \\n \\n\\n\\n1/5 \\n1/5 \\n \\n \\n \\n \\n \\n \\n \\nPress Release \\n \\n \\nDupixent approved in China as the first-ever biologic \\nmedicine for patients with COPD \\n \\n• \\nApproval follows EU approval of Dupixent for adults with COPD with raised blood \\neosinophils, and is based on two landmark phase 3 studies showing Dupixent \\nsignificantly reduced exacerbations, improved lung function, and also improved \\nhealth-related quality of life \\n• \\nCOPD is the most prevalent chronic respiratory disease in China, and is a priority \\nwithin the government’s Healthy China 2030 public health plan   \\n• \\nDupixent is now approved in four indications across respiratory and \\ndermatological diseases in China \\n \\nParis and Tarrytown, New York, Sept. 27, 2024. The National Medical Products \\nAdministration (NMPA) in China has approved Dupixent (dupilumab) as an add-on \\nmaintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease \\n(COPD) characterized by raised blood eosinophils. Specifically, the approval covers patients \\nalready on a combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist \\n(LABA) and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and \\na LAMA if ICS is not appropriate. Dupixent for the treatment of COPD has been approved in \\nmore than 30 countries worldwide, including the 27 countries in the EU. \\n \\nProfessor Kang Jian  \\nChair of COPD Branch, Chinese Association of Chest Physicians, CMDA, Respiratory \\nDepartment of First Hospital of China Medical University \\n“The impact of COPD extends far beyond the patient. Debilitating breathlessness and \\nirreversible lung damage make it difficult for patients to do simple daily tasks, placing a \\nsignificant burden on family members, the central caregivers in Chinese families. The approval \\nof Dupixent for COPD in China is critical, as it fills a gap in targeted therapy for the disease and \\nprovides clinicians with a new treatment approach. This offers new hope for COPD patients who \\nremain inadequately controlled even after triple therapy, as well as those who care for them.\\\" \\n \\nHouman Ashrafian, MD, PhD  \\nExecutive Vice President, Head of Research and Development at Sanofi  \\n“China has the largest number of people living with COPD worldwide, and a significant \\nproportion of patients are uncontrolled on current therapies and desperate for an effective \\ntreatment option. The Dupixent COPD clinical program has furthered our scientific \\nunderstanding of COPD, and given us a new way to think about which patients could benefit \\nmost from such a treatment. With its well-established safety and efficacy profile, Dupixent is a \\nlong-awaited advancement for patients, caregivers, and physicians who are desperate for a \\nnew treatment option.” \\n \\nDespite the high prevalence and burden of COPD in China, public awareness is limited. The \\nHealthy China 2030 public health initiative includes a focus on addressing chronic respiratory \\ndiseases like COPD and aims to improve the quality of life for patients with COPD.  \\n\\n\\n2/5 \\n2/5 \\n \\n \\n \\n \\n \\n \\n \\n \\nThe approval is based on results from the landmark BOREAS and NOTUS phase 3 studies, \\nwhich evaluated the efficacy and safety of Dupixent in adults with uncontrolled COPD with \\nraised blood eosinophils. All patients were on background maximal standard-of-care inhaled \\ntherapy (nearly all on triple therapy). Dupixent significantly reduced COPD exacerbations by \\n30% and 34% compared to placebo in the BOREAS and NOTUS studies respectively. Dupixent \\nsignificantly and rapidly improved lung function compared to placebo, with improvements \\nsustained at 52 weeks. Improvements in health-related quality of life (statistically significant \\nin BOREAS and nominally significant in NOTUS) compared to placebo were also observed, as \\nassessed by the St. George’s Respiratory Questionnaire (SGRQ). Data from both studies were \\npublished in separate manuscripts in The New England Journal of Medicine (BOREAS and \\nNOTUS). \\n \\nSafety results in both studies were generally consistent with the known safety profile of \\nDupixent in its approved indications. The most common side effects across indications include \\ninjection site reactions, conjunctivitis, conjunctivitis allergic, arthralgia, oral herpes, and \\neosinophilia. Additional adverse reactions of injection site bruising, injection site induration, \\ninjection site rash, and injection site dermatitis were reported in the COPD studies. Adverse \\nevents more commonly observed with Dupixent (≥5%) compared to placebo in either COPD \\nstudy were back pain, COVID-19, diarrhea, headache, and nasopharyngitis.  \\n \\nGeorge D. Yancopoulos, M.D., Ph.D. \\nBoard co-Chair, President, and Chief Scientific Officer at Regeneron  \\n“One in four people with COPD live in China, and many patients are unable to control their \\ndisease with standard of care treatments and experience repeated hospitalizations from \\nexacerbations and debilitating limitations on their quality of life. With millions of people in \\nindustrialized areas worldwide facing increased risk for developing COPD, it is more important \\nthan ever to deliver innovative new options for this complex and notoriously difficult-to-treat \\ndisease. With this latest Dupixent approval, patients in China have a novel treatment approach \\nthat has shown groundbreaking results by reducing exacerbations while also improving lung \\nfunction and supporting a better quality of life.” \\n \\nAdditional submissions for Dupixent in COPD are under review with regulatory authorities \\naround the world, including in the US and Japan. \\n \\nAbout COPD \\nCOPD is a respiratory disease that damages the lungs and causes progressive lung function \\ndecline. Symptoms include persistent cough, excessive mucus production, and shortness of \\nbreath that may impair the ability to perform routine daily activities, which may lead to sleep \\ndisturbances, anxiety and depression. COPD is also associated with a significant health and \\neconomic burden due to recurrent acute exacerbations that require systemic corticosteroid \\ntreatment and/or lead to hospitalization. Smoking and exposure to noxious particles are key \\nrisk factors for COPD, but even individuals who quit smoking can still have progressive lung \\ndisease.  \\n \\nAbout half of COPD patients continue to experience exacerbations despite being on triple \\ninhaled therapy. Patients with an eosinophilic phenotype contribute to a ~30% increase in \\nexacerbations and an increased risk of COPD-related re-hospitalizations within a year. \\n \\n \\n \\n\\n\\n3/5 \\n3/5 \\n \\n \\n \\n \\n \\n \\n \\nAbout Sanofi and Regeneron’s COPD Clinical Research Program \\nSanofi and Regeneron are motivated to transform the treatment paradigm of COPD by \\nexamining the role different types of inflammation play in the disease progression through \\nthe investigation of two potentially first-in-class biologics, Dupixent and itepekimab. \\n \\nDupixent inhibits the signaling of the interleukin-4 (IL4) and interleukin-13 (IL13) pathways \\nand the program focuses on a specific population of people with evidence of type-2 \\ninflammation. Itepekimab is a fully human monoclonal antibody that binds to and inhibits \\ninterleukin-33 (IL33), an initiator and amplifier of broad inflammation in COPD. \\n \\nItepekimab is currently under clinical investigation for COPD in two phase 3 studies and its \\nsafety and efficacy have not been evaluated by any regulatory authority. \\n \\nAbout Dupixent \\nDupixent is available in China in a 300 mg dose as a pre-filled syringe or pre-filled pen and is \\nnow available for COPD. Dupixent is intended for injection under the skin (subcutaneous \\ninjection) and is given every other week. It can be given in a clinic or at home by self-\\nadministration after training by a healthcare professional. \\n \\nDupixent (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the \\ninterleukin-4 (IL4) and interleukin-13 (IL13) pathways and is not an immunosuppressant. The \\nDupixent development program has shown significant clinical benefit and a decrease in type-\\n2 inflammation in phase 3 studies, establishing that IL4 and IL13 are key and central drivers \\nof the type-2 inflammation that plays a major role in multiple related and often co-morbid \\ndiseases. \\n \\nDupixent has received regulatory approvals in more than 60 countries in one or more \\nindications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis \\nwith nasal polyps, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria, \\nand COPD in different age populations. More than 1,000,000 patients are being treated with \\nDupixent globally. \\n \\nDupilumab development program \\nDupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration \\nagreement. To date, dupilumab has been studied across more than 60 clinical studies \\ninvolving more than 10,000 patients with various chronic diseases driven in part by type-2 \\ninflammation. \\n \\nIn addition to the currently approved indications, Sanofi and Regeneron are studying \\ndupilumab in a broad range of diseases driven by type-2 inflammation or other allergic \\nprocesses in phase 3 studies, including chronic pruritus of unknown origin and bullous \\npemphigoid. These potential uses of dupilumab are currently under clinical investigation, and \\nthe safety and efficacy in these conditions have not been fully evaluated by any regulatory \\nauthority. \\n \\nAbout Regeneron \\nRegeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and \\ncommercializes life-transforming medicines for people with serious diseases. Founded and led \\nby physician-scientists, our unique ability to repeatedly and consistently translate science into \\nmedicine has led to numerous approved treatments and product candidates in development, \\n\\n\\n4/5 \\n4/5 \\n \\n \\n \\n \\n \\n \\n \\nmost of which were homegrown in our laboratories. Our medicines and pipeline are designed \\nto help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular \\nand metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, \\nand rare diseases. \\n \\nRegeneron pushes \\nthe \\nboundaries \\nof \\nscientific \\ndiscovery \\nand accelerates \\ndrug \\ndevelopment using our proprietary technologies, such as VelociSuite®, which produces \\noptimized fully human antibodies and new classes of bispecific antibodies. We are shaping the \\nnext frontier of medicine with data-powered insights from the Regeneron Genetics \\nCenter® and pioneering genetic medicine platforms, enabling us to identify innovative targets \\nand complementary approaches to potentially treat or cure diseases. \\n \\nFor more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, \\nInstagram, Facebook or X. \\n \\nAbout Sanofi  \\nWe are an innovative global healthcare company, driven by one purpose: we chase the \\nmiracles of science to improve people’s lives. Our team, across the world, is dedicated to \\ntransforming the practice of medicine by working to turn the impossible into the possible. We \\nprovide potentially life-changing treatment options and life-saving vaccine protection to \\nmillions of people globally, while putting sustainability and social responsibility at the center \\nof our ambitions.  \\nSanofi is listed on EURONEXT: SAN and NASDAQ: SNY \\n \\nSanofi Media Relations \\nSandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.com \\nEvan Berland | + 1 215 432 0234 | evan.berland@sanofi.com \\nVictor Rouault | + 33 6 70 93 71 40 | victor.rouault@sanofi.com \\nTimothy Gilbert | + 1 516 521 2929 | timothy.gilbert@sanofi.com \\n \\nSanofi Investor Relations \\nThomas Kudsk Larsen |+ 44 7545 513 693 | thomas.larsen@sanofi.com \\nAlizé Kaisserian | + 33 6 47 04 12 11 | alize.kaisserian@sanofi.com \\nArnaud Delépine | + 33 6 73 69 36 93 |arnaud.delepine@sanofi.com \\nFelix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.com \\nKeita Browne | + 1 781 249 1766 | keita.browne@sanofi.com \\nNathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.com \\nTarik Elgoutni | + 1 617 710 3587 | tarik.elgoutni@sanofi.com  \\nThibaud Châtelet | + 33 6 80 80 89 90 | thibaud.chatelet@sanofi.com \\n \\nRegeneron Media Relations \\nHannah Kwagh | +1 914-847-6314| hannah.kwagh@regeneron.com   \\n  \\nRegeneron Investor Relations \\nVesna Tosic | + 914-847-5443 | vesna.tosic@regeneron.com \\n \\n \\n \\n \\nSanofi forward-looking statements \\nThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. \\nForward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding \\nthe marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements \\nare generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. \\nAlthough Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors \\nare cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are \\ndifficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially \\n\\n\\n5/5 \\n5/5 \\n \\n \\n \\n \\n \\n \\n \\nfrom those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties \\ninclude among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the \\navailability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent \\nin research and development, including future clinical data and analysis of existing clinical data relating to the product, including post \\nmarketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and \\nany related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact \\nthat pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the \\nfinancial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties \\nalso include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those \\nlisted under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-\\nF for the year ended December 31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation to \\nupdate or revise any forward-looking information or statements. \\n \\nAll trademarks mentioned in this press release are the property of the Sanofi group with the exception of VelociSuite and Regeneron \\nGenetics Center. \\n \\nRegeneron Forward-Looking Statements and Use of Digital Media  \\nThis press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future \\nperformance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially \\nfrom these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations \\nof such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking \\nstatements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the \\nnature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron \\nand/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron \\nand/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research and clinical programs now underway \\nor planned, including without limitation Dupixent® (dupilumab) as an add-on maintenance treatment for adults with uncontrolled \\nchronic obstructive pulmonary disease characterized by raised blood eosinophils (“COPD”); uncertainty of the utilization, market \\nacceptance, and commercial success of Regeneron’s Products and Regeneron’s Product Candidates and the impact of studies (whether \\nconducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press \\nrelease, on any of the foregoing or any potential regulatory approval of Regeneron’s Products (such as Dupixent) and Regeneron’s \\nProduct Candidates (such as itepekimab); the likelihood, timing, and scope of possible regulatory approval and commercial launch of \\nRegeneron’s Product Candidates and new indications for Regeneron’s Products, such as Dupixent for the treatment of COPD in the \\nUnited States, Japan, and other jurisdictions as well as Dupixent for the treatment of chronic pruritus of unknown origin, bullous \\npemphigoid, and other potential indications; the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as \\napplicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s \\nProducts and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product \\ncandidates; safety issues resulting from the administration of Regeneron’s Products (such as Dupixent) and Regeneron’s Product \\nCandidates (such as itepekimab) in patients, including serious complications or side effects in connection with the use of Regeneron’s \\nProducts and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental \\nauthorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and \\nRegeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical \\nprograms, and business, including those relating to patient privacy; the availability and extent of reimbursement of Regeneron’s \\nProducts from third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, \\npharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement \\ndeterminations by such payers and new policies and procedures adopted by such payers; competing drugs and product candidates \\nthat may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates; the extent to which \\nthe results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be \\nreplicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory \\napproval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of \\nits financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any \\nlicense, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated \\ncompanies, as applicable) to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics (such as the \\nCOVID-19 pandemic) on Regeneron's business; and risks associated with intellectual property of other parties and pending or future \\nlitigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® \\n(aflibercept) Injection), other litigation and other proceedings and government investigations relating to the Company and/or its \\noperations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office \\nfor the District of Massachusetts), the ultimate outcome of any such proceedings and investigations, and the impact any of the \\nforegoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of \\nthese and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its \\nForm 10-K for the year ended December 31, 2023 and its Form 10-Q for the quarterly period ended June 30, 2024. Any forward-\\nlooking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any \\nforward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any \\nforward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, \\nfuture events, or otherwise.  \\n \\nRegeneron uses its media and investor relations website and social media outlets to publish important information about the Company, \\nincluding information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted \\nand is accessible on Regeneron's media and investor relations website (https://investor.regeneron.com) and its LinkedIn page \\n(https://www.linkedin.com/company/regeneron-pharmaceuticals). \\n\\n\\n1/6 \\n \\n \\n \\n \\n \\nPress Release \\n \\n \\nDupixent approved in the US as the first-ever biologic \\nmedicine for patients with COPD \\n \\n \\n• \\nDupixent is indicated for the approximately 300,000 adults in the US with inadequately \\ncontrolled COPD and an eosinophilic phenotype  \\n• \\nFollowing recent approvals in the EU and China, the US approval is based on two \\nlandmark phase 3 studies that showed Dupixent achieved significant reduction in \\nexacerbations, and also showed improvements in lung function and health-related \\nquality of life compared to placebo \\n• \\nDupixent is the leading biologic medicine for all of its FDA-approved indications in \\nnew-to-brand prescriptions, and the most prescribed biologic by pulmonologists in \\nthe US \\n \\nParis and Tarrytown, NY, September 27, 2024. The US Food and Drug Administration \\n(FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults \\nwith inadequately controlled chronic obstructive pulmonary disease (COPD) and an \\neosinophilic phenotype. Dupixent is the first biologic medicine approved in the US to treat \\nthese patients.  \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n  \\n \\n \\n \\n \\n \\n \\n \\n \\n \\nJean Wright, M.D.\\nChief Executive Officer at The COPD Found欧洲净零工业法案ation\\n“People living with inadequately controlled COPD have long awaited new medicines to help \\nmanage the daily suffering they experience from breathlessness, coughing, wheezing, \\nexhaustion and unpredictable hospitalization. These patients often struggle with everyday \\nactivities many people take for granted such as taking a walk or running errands outside the \\nhome. We welcome the approval of this new therapeutic option to offer patients a new way to \\nhelp gain better control of their disease.”\\nPaul Hudson\\nChief Executive Officer at Sanofi\\n“Dupixent has already shown it can revolutionize the treatment paradigm of many diseases \\ndriven in part by type 2 inflammation with high unmet medical needs, with one million patients\\nbeing treated globally across all currently approved indications. With today’s approval, \\nDupixent once again paves the way and becomes the first and only approved add-on biologic \\nmedicine for inadequately controlled COPD, giving patients living with this devastating \\ndisease the chance to look forward to the potential of improved breathing and a life with fewer \\nexacerbations.”\\nThe FDA approval is based on data from two landmark pivotal phase 3 studies (BOREAS and \\nNOTUS) that evaluated the efficacy and safety of Dupixent compared to placebo in adults \\ncurrently on maximal standard-of-care inhaled therapy (nearly all on triple therapy) with \\ninadequately controlled COPD and blood eosinophils ≥300 cells per µL. Patients who \\nreceived Dupixent in BOREAS (n=468) and NOTUS (n=470) experienced the following \\noutcomes, respectively, compared to placebo (BOREAS n=471; NOTUS n=465):\\n\\n\\n2/6 \\n \\n \\n \\n \\n \\n• \\n30% and 34% reduction in the annualized rate of moderate or severe COPD \\nexacerbations over 52 weeks, the primary endpoint. \\n• \\n74mL and 68mL numerically greater improvements in post-bronchodilator FEV1 \\nfrom baseline at week 12 compared to placebo, sustained at 52 weeks. Statistically \\nsignificant improvements of similar magnitude were observed in pre-bronchodilator \\nFEV1 from baseline at 12 and 52 weeks, a key secondary endpoint.  \\n• \\n51% response in a health-related quality of life measure in both trials compared to \\n43% and 47% with placebo at 52 weeks, as assessed by a 4-point improvement \\non the St. George’s Respiratory Questionnaire (SGRQ). \\n \\n \\nSafety results in both studies were generally consistent with the known safety profile of \\nDupixent in its approved indications. In pooled BOREAS and NOTUS data, the most common \\nadverse events (>2%) more frequently observed in patients on Dupixent compared to \\nplacebo were viral infection, headache, nasopharyngitis, back pain, diarrhea, arthralgia, \\nurinary tract infection, local administration reaction, rhinitis, eosinophilia, toothache, and \\ngastritis. While less common, cholecystitis was reported in 0.6% of patients on Dupixent \\ncompared to 0.1% of patients on placebo. \\n \\nGeorge D. Yancopoulos, M.D., Ph.D. \\nBoard Co-Chair, President and Chief Scientific Officer at Regeneron \\n“This latest FDA approval for Dupixent represents new hope for the hundreds of thousands of \\nCOPD patients in the US who can sometimes struggle just to breathe during their everyday \\nlives. Dupixent has a proven track record as a first-in-class medicine, providing benefit to the \\nmany patients suffering from type 2 inflammatory related diseases such as asthma and atopic \\ndermatitis. This latest approval represents an important next chapter for Dupixent, giving \\nthose with COPD a novel option that has demonstrated the unprecedented ability to help \\npatients experience fewer exacerbations, while also helping them breathe better and improve \\nquality of life in phase 3 studies.” \\n \\nThe FDA evaluated Dupixent under Priority Review, which is reserved for medicines that \\nrepresent potentially significant improvements in efficacy or safety in treating serious \\nconditions. In July 2024, Sanofi and Regeneron announced that the European Medicines \\nAgency approved Dupixent as an add-on maintenance treatment for adults with \\nuncontrolled COPD characterized by raised blood eosinophils. Submissions are currently \\nunder review with other regulatory authorities around the world, including in Japan. \\n \\nAbout COPD \\nCOPD is a respiratory disease that damages the lungs and causes progressive lung function \\ndecline and is the fourth leading cause of death worldwide. Symptoms include persistent \\ncough, excessive mucus production and shortness of breath that may impair the ability to \\nperform routine daily activities, which may lead to sleep disturbances, anxiety, and \\ndepression. COPD is also associated with a significant health and economic burden due to \\nrecurrent acute exacerbations that require systemic corticosteroid medicine and/or \\nantibiotics. Smoking and exposure to noxious particles are key risk factors for COPD, but \\neven individuals who quit smoking can still have progressive lung disease.  \\n \\nAbout half of COPD patients continue to experience exacerbations despite being on triple \\ninhaled therapy. In the US, approximately 300,000 people live with inadequately controlled \\nCOPD and an eosinophilic phenotype. Patients with an eosinophilic phenotype contribute to \\nan ~30% increase in exacerbations and an increased risk of COPD-related re-\\nhospitalizations within a year. \\n \\n\\n\\n3/6 \\n \\n \\n \\n \\n \\nAbout the Dupixent COPD phase 3 study program \\nBOREAS and NOTUS were replicate, randomized, phase 3, double-blind, placebo-controlled \\nstudies that evaluated the efficacy and safety of Dupixent in adults who were current or \\nformer smokers with moderate-to-severe COPD with an eosinophilic phenotype, as defined \\nby blood eosinophils ≥300 cells per µL. The studies included adults with COPD across a \\nbroad range of clinical presentations, including those with chronic bronchitis and \\nemphysema. The studies enrolled 1,874 patients who were aged 40 to 80 years in BOREAS \\nand 40 to 85 years in NOTUS. \\n \\nDuring the 52-week treatment period, patients in BOREAS and NOTUS received Dupixent or \\nplacebo every two weeks added to a maximal standard-of-care inhaled triple therapy of ICS, \\nLABA and LAMA. Double maintenance therapy, which included LABA and LAMA, was allowed \\nif ICS was not appropriate. \\n \\nThe primary endpoint for BOREAS and NOTUS evaluated the annualized rate of acute \\nmoderate or severe COPD exacerbations. Key secondary endpoints included change from \\nbaseline in lung function (assessed by pre-bronchodilator forced expiratory volume [FEV1]) \\nat 12 and 52 weeks, change from baseline at 52 weeks in SGRQ total score compared to \\nplacebo, and safety. \\n \\nThe results of both BOREAS and NOTUS were separately published in The New England \\nJournal of Medicine. \\n \\nAbout Sanofi and Regeneron’s COPD Clinical Research Program \\nSanofi and Regeneron are motivated to transform the treatment paradigm of COPD by \\nexamining the role different types of inflammation play in the disease progression through \\nDupixent, a first-in-class biologic, and the investigation of itepekimab. \\n \\nDupixent inhibits the signaling of the interleukin-4 (IL4) and interleukin-13 (IL13) pathways \\nand the program focuses on a specific population of people with evidence of type 2 \\ninflammation. Itepekimab is a fully human monoclonal antibody that binds to and inhibits \\ninterleukin-33 (IL33), an initiator and amplifier of broad inflammation in COPD. \\n \\nItepekimab is currently under clinical investigation for COPD in two phase 3 studies and its \\nsafety and efficacy have not been evaluated by any regulatory authority. \\n \\nAbout Dupixent \\nDupixent is a fully human monoclonal antibody that inhibits the signaling of the IL4 and \\nIL13 pathways and is not an immunosuppressant. The Dupixent development program has \\nshown significant clinical benefit and a decrease in type 2 inflammation in phase 3 studies, \\nestablishing that IL4 and IL13 are two of the key and central drivers of type 2 inflammation \\nthat play a major role in multiple related and often co-morbid diseases. \\n \\nSanofi and Regeneron are committed to helping patients in the US who are prescribed \\nDupixent gain access to the medicine and receive the support they may need with the \\nDUPIXENT MyWay® program. For more information, please call 1-844-DUPIXENT (1-844-\\n387-4936) or visit www.DUPIXENT.com. \\n \\nDupixent has received regulatory approvals in more than 60 countries in one or more \\nindications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis \\nwith nasal polyps, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria, \\n\\n\\n4/6 \\n \\n \\n \\n \\n \\nand COPD in different age populations. More than 1,000,000 patients are being treated with \\nDupixent globally. \\n \\nDupilumab Development Program \\nDupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration \\nagreement. To date, dupilumab has been studied across more than 60 clinical studies \\ninvolving more than 10,000 patients with various chronic diseases driven in part by type 2 \\ninflammation. \\n \\nIn addition to the currently approved indications, Sanofi and Regeneron are studying \\ndupilumab in a broad range of diseases driven in part by type 2 inflammation or other \\nallergic processes in phase 3 studies, including chronic pruritus of unknown origin and \\nbullous pemphigoid. These potential uses of dupilumab are currently under clinical \\ninvestigation, and the safety and efficacy in these conditions have not been fully evaluated \\nby any regulatory authority. \\n \\nAbout Regeneron \\nRegeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and \\ncommercializes life-transforming medicines for people with serious diseases. Founded and \\nled by physician-scientists, our unique ability to repeatedly and consistently translate \\nscience into medicine has led to numerous approved treatments and product candidates in \\ndevelopment, most of which were homegrown in our laboratories. Our medicines and \\npipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, \\ncancer, cardiovascular and metabolic diseases, neurological diseases, hematologic \\nconditions, infectious diseases, and rare diseases. \\n \\nRegeneron pushes the boundaries of scientific discovery and accelerates drug \\ndevelopment using our proprietary technologies, such as VelociSuite®, which produces \\noptimized fully human antibodies and new classes of bispecific antibodies. We are shaping \\nthe next frontier of medicine with data-powered insights from the Regeneron Genetics \\nCenter® and pioneering genetic medicine platforms, enabling us to identify innovative \\ntargets and complementary approaches to potentially treat or cure diseases. \\n \\nFor more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, \\nInstagram, Facebook or X. \\n \\nAbout Sanofi  \\nWe are an innovative global healthcare company, driven by one purpose: we chase the \\nmiracles of science to improve people’s lives. Our team, across the world, is dedicated to \\ntransforming the practice of medicine by working to turn the impossible into the possible. \\nWe provide potentially life-changing treatment options and life-saving vaccine protection to \\nmillions of people globally, while putting sustainability and social responsibility at the center \\nof our ambitions.  \\nSanofi is listed on EURONEXT: SAN and NASDAQ: SNY \\n \\nMedia Relations \\nSandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.com \\nEvan Berland | +1 215 432 0234 | evan.berland@sanofi.com  \\nNicolas Obrist | + 33 6 77 21 27 55 | nicolas.obrist@sanofi.com  \\nVictor Rouault | + 33 6 70 93 71 40 | victor.rouault@sanofi.com \\nTimothy Gilbert | + 1 516 521 2929 | timothy.gilbert@sanofi.com \\n \\nInvestor Relations \\n\\n\\n5/6 \\n \\n \\n \\n \\n \\nThomas Kudsk Larsen |+ 44 7545 513 693 | thomas.larsen@sanofi.com  \\nAlizé Kaisserian | + 33 6 47 04 12 11 | alize.kaisserian@sanofi.com \\nArnaud Delépine | + 33 6 73 69 36 93 | arnaud.delepine@sanofi.com \\nFelix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.com  \\nKeita Browne | + 1 781 249 1766 | keita.browne@sanofi.com \\nNathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.com \\nTarik Elgoutni | + 1 617 710 3587 | tarik.elgoutni@sanofi.com  \\nThibaud Châtelet | + 33 6 80 80 89 90 | thibaud.chatelet@sanofi.com \\n \\nRegeneron Media Relations \\nHannah Kwagh | +1 914 847 6314| hannah.kwagh@regeneron.com \\n \\nRegeneron Investor Relations \\nVesna Tosic | + 914 847 5443 | vesna.tosic@regeneron.com \\n \\n \\nSanofi Forward-Looking Statements \\nThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. \\nForward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding \\nthe marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements \\nare generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. \\nAlthough Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors \\nare cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are \\ndifficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially \\nfrom those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties \\ninclude among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the \\navailability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent \\nin research and development, including future clinical data and analysis of existing clinical data relating to the product, including post \\nmarketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and \\nany related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact \\nthat pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the \\nfinancial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties \\nalso include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those \\nlisted under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-\\nF for the year ended December 31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation to \\nupdate or revise any forward-looking information or statements. \\n \\nAll trademarks mentioned in this press release are the property of the Sanofi group apart from VelociSuite and Regeneron Genetics \\nCenter.  \\n \\nRegeneron Forward-Looking Statements and Use of Digital Media \\nThis press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future \\nperformance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially \\nfrom these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” \\nvariations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-\\nlooking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among \\nothers, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by \\nRegeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by \\nRegeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research and clinical programs \\nnow underway or planned, including without limitation Dupixent® (dupilumab) as an add-on maintenance treatment of adults with \\ninadequately controlled chronic obstructive pulmonary disease (“COPD”) and an eosinophilic phenotype; uncertainty of the utilization, \\nmarket acceptance, and commercial success of Regeneron’s Products and Regeneron’s Product Candidates and the impact of studies \\n(whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in \\nthis press release, on any of the foregoing or any potential regulatory approval of Regeneron’s Products (such as Dupixent) and \\nRegeneron’s Product Candidates (such as itepekimab); the likelihood, timing, and scope of possible regulatory approval and \\ncommercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products, such as Dupixent for the \\ntreatment of COPD in Japan and other jurisdictions as well as Dupixent for the treatment of chronic pruritus of unknown origin, bullous \\npemphigoid, and other potential indications; the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as \\napplicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s \\nProducts and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product \\ncandidates; safety issues resulting from the administration of Regeneron’s Products (such as Dupixent) and Regeneron’s Product \\nCandidates (such as itepekimab) in patients, including serious complications or side effects in connection with the use of Regeneron’s \\nProducts and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental \\nauthorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and \\nRegeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical \\nprograms, and business, including those relating to patient privacy; the availability and extent of reimbursement of Regeneron’s \\nProducts from third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, \\npharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement \\ndeterminations by such payers and new policies and procedures adopted by such payers; competing drugs and product candidates \\nthat may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates; the extent to which \\nthe results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be \\n\\n\\n6/6 \\n \\n \\n \\n \\n \\nreplicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory \\napproval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of \\nits financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any \\nlicense, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated \\ncompanies, as applicable) to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics (such as the \\nCOVID-19 pandemic) on Regeneron's business; and risks associated with intellectual property of other parties and pending or future \\nlitigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® \\n(aflibercept) Injection), other litigation and other proceedings and government investigations relating to the Company and/or its \\noperations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office \\nfor the District of Massachusetts), the ultimate outcome of any such proceedings and investigations, and the impact any of the \\nforegoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of \\nthese and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its \\nForm 10-K for the year ended December 31, 2023 and its Form 10-Q for the quarterly period ended June 30, 2024. Any forward-\\nlooking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any \\nforward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any \\nforward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, \\nfuture events, or otherwise. \\n \\nRegeneron uses its media and investor relations website and social media outlets to publish important information about the Company, \\nincluding information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted \\nand is accessible on Regeneron's media and investor relations website (https://investor.regeneron.com) and its LinkedIn page \\n(https://www.linkedin.com/company/regeneron-pharmaceuticals).\",\"difficulty\":\"hard\",\"domain\":\"Multi-Document QA\",\"length\":\"short\",\"question\":\"Based on the press release about Sanofi's product Dupixent, how do you know about its indication treatment?\",\"sub_domain\":\"Multi-news\"}","display_format":"text","language":"","answer_status":"published","assets":[],"source_url":"https://huggingface.co/datasets/zai-org/LongBench-v2","history":"initial import","indexing_mode":"noindex","subproblems":[],"grids":[]}